CD79A and nasopharyngeal carcinoma: Our previous studies have demonstrated that serum immunoglobulin A (IgA) antibodies against EBV nuclear antigen 1 (EBNA1/IgA) and viral capsid antigen (VCA/IgA) serve as serological biomarkers of EBV activation and are effective in predicting nasopharyngeal cancer (9, 10).